New drug for persistent anal HPV16 infection
Part of Infections clinical trials.
This trial tests a new drug (NWRD09) for people who have had HPV type 16 infection in the anal area for over a year. It aims to see if the drug can help clear the virus without causing serious side effects.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 60 years old.
- You have had HPV type 16 in the anal area for at least 12 months.
- Your anal biopsy shows either no abnormal cells, mild inflammation, or a low-grade lesion (not high-grade or cancer).
- You have adequate organ function (kidneys, liver, bone marrow) based on recent blood tests.
- If you can become pregnant, you must have a negative pregnancy test and use highly effective birth control during and for 6 months after the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new treatment called NWRD09 for women with a long-lasting HPV16 infection that shows concerning cell changes in the cervix. The goal is to see if this treatment can help your immune system clear the infection and prevent it from developing into cervical cancer.
This trial tests an experimental treatment called NWRD09 for women who have had a persistent HPV 16 infection for at least 12 months. The goal is to see if it can clear the virus and prevent cervical changes.
This trial tests a new drug called NWRD09 for women with high-grade cervical cell changes (CIN 2/3) caused by HPV type 16. The goal is to see if the drug can help clear these abnormal cells without needing surgery.
This trial tests a new drug called NWRD09 for women with a high-grade precancerous cervical condition caused by HPV type 16. If you qualify, you would receive the study drug and be monitored to see if it can help clear the abnormal cells.
This study tests a new treatment (NWRD08) for women with high-grade cervical changes (CIN 2/3) caused by HPV types 16 or 18. It aims to see if the treatment can help clear the abnormal cells and prevent them from becoming cancer.
This trial tests a new medicine called NWRD09 for people with HPV-16 related cervical cell changes (HSIL) or advanced cervical cancer. The goal is to see if it can help treat these conditions.
Hear when a new Persistent HPV16 Infection trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.